Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia

Trial ID or NCT#



not recruiting iconNOT RECRUITING


This clinical trial is studying the side effects of Erwinia asparaginase and what happens to the drug in the body in treating young patients with acute lymphoblastic leukemia who are allergic to PEG-asparaginase. Drugs used in chemotherapy, such as Erwinia asparaginase, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.

Official Title

Pharmacology and Toxicity of Erwinia Asparaginase (Erwinase?; Crisantaspase; IND 290) Following Allergy to PEG-Asparaginase in Treatment of Children With Acute Lymphoblastic Leukemia (ALL)

Eligibility Criteria

Ages Eligible for Study: 1 Year to 30 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


Neyssa Marina

Contact us to find out if this trial is right for you.


Peds Hem/Onc CRAs